

June 26, 2018

Subject: DISCONTINUATION OF TAXOTERE® 80 mg (docetaxel for injection)

Dear Healthcare Professional,

Sanofi Genzyme, a division of sanofi-aventis Canada Inc., would like to inform you that Taxotere® 80 mg (docetaxel for injection) will be discontinued. It should be noted that, exceptionally, Sanofi Canada will distribute the remaining inventory of Taxotere® 80 mg until stock depletion to accommodate demand. The table below provides a summary of the supply situation. The final stock depletion date will be noted on the www.drugshortagescanada.ca website.

DIN	UPC	Description	Format	Anticipated Final Dates of Distribution
02177080	6 22337 76580 5	Taxotere 80 mg/2 mL	1 vial	December 31, 2018

We apologize for any inconvenience this may cause you. Should you have any questions regarding this subject, please do not hesitate to call Customer Service at 1-800-265-7927.

Sincerely,



Nicole Pohlmann
Marketing Lead – Oncology